Spondyloarthropathy and idiopathic inflammatory bowel diseases

Inflammatory Bowel Diseases

Volumn 3, Issue 1, 1997, Pages 25-37

  Meuwissen, Stephan G M ^a   Crusius, J Bart A ^a   Peña, A Salvador ^a   Dekker Saeys, Alberta J ^b   Dijkmans, Ben A C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JAN VAN BREEMEN INSTITUTE   (Netherlands)

Author keywords

Ankylosing spondylitis; Arthritis; Campylobacter; Chlamydia; Crohn's disease; Cytokines; Genetics; HLA antigens; HLA B27; NSAID; Reactive arthritis; Sacroiliitis; Salmonella; Shigella; Sulfasalazine; T lymphocyte; Tumor necrosis factor; Ulcerative colitis; Yersinia

Indexed keywords

EID: 0002050775     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1002/ibd.3780030107     Document Type: Review

References (168)

1. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, Cats A, Dijkmans B, Olivieri I, Pasero G, Veys E, Zeidler H. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-27.
2. Palumbo PJ, Ward LE, Sauer WG, Scudamore HH. Musculoskeletal manifestations of inflammatory bowel disease: ulcerative and granulomatous colitis and ulcerative proctitis. Mayo Clin Proc 1973;48:411-6.
3. Gravallese EM, Kantrowitz FG. Arthritic manifestations of inflammatory bowel disease. Am J Gastroenterol 1988; 83:703-9.
4. Haslock I. Arthritis and Crohn's disease: a family study. Ann Rheum Dis 1973;32:479-86.
5. Wright V, Watkinson G. The arthritis of ulcerative colitis. Br Med J 1965;2:670-5.
6. Dekker-Saeys BJ, Meuwissen SGM, van den Berg-Loonen EM, de Haas WH, Agenant D, Tytgat GN. Ankylosing spondylitis and inflammatory bowel disease. II. Prevalence of peripheral arthritis, sacroiliitis, and ankylosing spondylitis in patients suffering from inflammatory bowel disease. Ann Rheum Dis 1978;37:33-5.
7. McCulloch DK, Fraser DM, Turner AL. Arthritis preceding fulminant ulcerative colitis and responding to colectomy. Br Med J 1980;281:839.
8. Wolheim FA. Enteropathic arthritis. In: Kelley WN, Harris ED, Suddy S, Sledge CB, eds. Textbook of rheumatology, 4th ed, vol 1. Philadelphia, London, Toronto, Montreal, Sydney, Tokyo: WB Saunders, 1993:985-97.
9. Andreyev HJN, Kamm MA, Forbes A, Nicholls RJ. Joint symptoms after restorative proctocolectomy in ulcerative colitis and familial polyposis coli. J Clin Gastroenterol 1996;23:35-9.
10. Wright V, Watkinson G. Sacroiliitis and ulcerative colitis. Br Med J 1965;2:675-80.
11. Haslock I, Wright V. The musculo-skeletal complications of Crohn's disease. Medicine 1973;52:217-25.
12. McEwen C, Lingg C, Kirsner JB, Spencer JA. Arthritis accompanying ulcerative colitis. Am J Med 1962;33:923-41.
13. Isdale A, Wright V. Seronegative arthritis and the bowel. Baillieres Clin Rheumatol 1989;3:285-301.
14. Monsén U, Sorstad J, Hellers G, Johansson C. Extracolonic diagnoses in ulcerative colitis: an epidemiological study. Am J Gastroenterol 1990;85:711-6.
15. Tavarela Veloso F, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease: a prospective study of 792 patients. J Clin Gastroenterol 1996;23:29-34.
16. Wright V, Watkinson G. The arthritis of ulcerative colitis. Medicine 1959;38:243-59.
17. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine 1976;55:401-12.
18. Rankin GB, Watts HD, Melnyk CS, Kelley ML. National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 1979;77:914-20.
19. Bhagat S, Das KM. A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody. Gastroenterology 1994;107:103-8.
20. Bywaters EGL, Ansell BM. Arthritis associated with ulcerative colitis. Ann Rheum Dis 1958;17:169-83.
21. Soren A. Joint affections in regional ileitis. Arch Intern Med 1966;117:78-83.
22. Heuman R, Boeryd B, Gillquist J, Sjodahl R, Tagesson C. Arthralgia and crystal deposits in Crohn's disease. Scand J Rheumatol 1981;10:313-7.
23. Hermans PJ, Fievez ML, Descamps CL, Aupaix MA. Granulomatous synovitis and Crohn's disease. J Rheumatol 1984;11:710-2.
24. Al-Hadidi S, Khatib G, Chhatwal P, Khatib R. Granulomatous arthritis in Crohn's disease. Arthritis Rheum 1984;27:1061-2.
25. Deshayes P, Le Loet X, Mejjad O, Daragon A, Pottier S. Erosive arthropathies in Crohn disease. Apropos of 3 cases. Rev Rhum Ed Fr 1993;60:625-7.
26. Beauvais C, Lequintrec JL, Prier A, Flipo RM, Kahn MF, Kaplan G. Destructive arthritis of the hip in Crohn's disease. Presse Med 1995;24:1555-8.
27. Axon JMC, Hawley PR, Huskisson EC. Ileal pouch arthritis. Br J Rheumatol 1993;32:586-8.
28. Merrett MN, Soper N, Mortensen N, Jewell DP. Intestinal permeability in the ileal pouch. Gut 1996;39:226-30.
29. Lohmuller JL, Pemberton JH, Dozois RR, Ilstrup D, van Heerden J. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. Ann Surg 1990;211:622-7.
30. Aisenberg J, Wagreich J, Shim J, Aimer S, Peen E, Heimann T, Gelernt IM, Greenstein A, Rubin P, Harpaz N, Sacher D. Perinuclear anti-neutrophil cytoplasmic antibody and refractory pouchitis: a case-control study. Dig Dis Sci 1995; 40:1866-72.
31. Acheson ED. An association between ulcerative colitis and regional enteritis and ankylosing spondylitis. Q J Med 1960;29:489-99.
32. Moll JM, Haslock I, Macrae IF, Wright V. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter's disease, the intestinal arthropathies, and Behcet's syndrome. Medicine 1974;53:343-64.
33. Dekker-Saeys AJ. Spondylitis ankylopoietica-syndroom [Thesis]. Amsterdam: University of Amsterdam, 1977:72.
34. Smith JN, Winship DH. Complications and extraintestinal problems in inflammatory bowel disease. Med Clin North Am 1980;64:1161-71.
35. Kennedy LG, Will R, Calin A. Sex ratio in the spondyloarthropathies and its relationship to phenotypic expression, mode of inheritance and age at onset. J Rheumatol 1993;20:1900-4.
36. Szanto E, Ruden B. 99mTc in evaluation of sacro-iliac arthritis. Scand J Rheumatol 1976;5:11-5.
37. Scott W, Fishman E, Kushman J. Computed tomography evaluation of the sacroiliac joints in Crohn's disease. Skel Radiol 1990;19:206-10.
38. McEniff N, Eustace S, McCarthy C, O'Malley M, O'Morain CA, Hamilton S. Asymptomatic sacroiliitis in inflammatory bowel disease - assessment by computed tomography. Clin Imaging 1995;19:258-62.
39. Braun J, Bollow M, Seyrekbasan F, Haberle HJ, Eggens U, Mertz A, Distler A, Sieper J. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis - clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol 1996;23:659-64.
40. Bollow M, Braun J, Hamm B, Eggens U, Schilling A, Konig H, Wolf KJ. Early sacroiliitis in patients with spondyloarthropathy: evaluation with dynamic gadolinium-enhanced MR imaging. Radiology 1995;194:529-36.
41. Battafarano DF, West SG, Rak KM, Fortenbery EJ, Chantelois AE. Comparison of bone scan, computed tomography, and magnetic resonance imaging in the diagnosis of active sacroiliitis. Semin Arthritis Rheum 1993;23:161-76.
42. Resnick D, Niwayama G, Goergen TG. Comparison of radiographic abnormalities of the sacroiliac joint in degenerative disease and ankylosing spondylitis. Am J Roentgenol 1977;128:189-96.
43. Mau W, Zeidler H, Mau R, Majewski A, Freyschmidt J, Stangel W, Deicher H. Clinical features and prognosis of patients with possible ankylosing spondylitis: results of a 10-year followup. J Rheumatol 1988;15:1109-14.
44. Scarpa R, del Puente A, D'Arienzo A, di Girolamo C, della Valle G, Panarese A, Lubrano E, Oriente P. The arthritis of ulcerative colitis: clinical and genetic aspects. J Rheumatol 1992;19:373-7.
45. Dekker-Saeys AJ, Keat ACS. Follow-up study of ankylosing spondylitis over a period of 12 years (1977-1989). Scand J Rheumatol 1990;(suppl 87):120-1.
46. Levine JB, Lukawskitrubish D. Extraintestinal considerations in inflammatory bowel disease. Gastroenterol Clin North Am 1995;24:633-46.
47. Sartor RB, Rath HC, Lichtman SN, van ToI EAF. Animal models of intestinal and joint inflammation. Baillieres Clin Rheumatol 1996;10:55-76.
48. Schlosstein L, Terasaki PI, Bluestone R, Pearson CM. High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med 1973;288:704-6.
49. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DCO, Sturrock RD. Ankylosing spondylitis and HL-A 27. Lancet 1973;1:904-7.
50. Khan MA, Khan MK. HLA-B27 as an aid to diagnosis of ankylosing spondylitis. Spine 1990;4:617-25.
51. Khan MA, van der Linden SM. Ankylosing spondylitis and other spondyloarthropathies. Rheum Dis Clin North Am 1990;16:551-79.
52. Khan MA. HLA-B27 and its subtypes in world populations. Curr Opin Rheumatol 1995;7:263-9.
53. van der Linden SM, Valkenburg HA, de Jongh BM, Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals: a comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 1984;27:241-9.
54. Khan MA. An overview of clinical spectrum and heterogeneity of spondyloarthropathies. Rheum Dis Clin North Am 1992;18:1-10.
55. Braun J, Sieper J. The sacroiliac joint in the spondyloarthropathies. Curr Opin Rheumatol 1996;8:275-87.
56. Dekker-Saeys BJ, Meuwissen SG, van den Berg-Loonen EM, de Haas WH, Meijers KA, Tytgat GN. Ankylosing spondylitis and inflammatory bowel disease. III. Clinical characteristics and results of histocompatibility typing (HLA B27) in 50 patients with both ankylosing spondylitis and inflammatory bowel disease. Ann Rheum Dis 1978;37:36-41.
57. Hyla JF, Franck WA, Davis JS. Lack of association of HLA B27 with radiographic sacroiliitis in inflammatory bowel disease. J Rheumatol 1976;3:196-200.
58. Taurog JD, Lowen L, Forman J, Hammer RE. HLA-B27 in inbred and non-inbred transgenic mice: cell surface expression and recognition as an alloantigen in the absence of human beta 2-microglobulin. J Immunol 1988;141:4020-3.
59. Nickerson CL, Luthra HS, David CS. Role of enterobacteria and HLA-B27 in spondyloarthropathies: studies with transgenic mice. Ann Rheum Dis 1990;49:426-33.
60. Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell 1990;63:1099-112.
61. Taurog JD, Maika SD, Simmons WA, Breban M, Hammer RE. Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression. J Immunol 1993;150:4168-78.
62. Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernndez-Sueiro JL, Balish E, Hammer RE. The germ-free state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994;180:2359-64.
63. Rath HC, Bender DE, Grenther T, Holt LC, Herfarth HH, Mohanty S, Taurog JD, Hammer RE, Sartor RB. Normal bacteria stimulate colonic, gastric and systemic inflammation in HLA-B27/beta2m transgenic rats. Gastroenterology 1995;108:899A.
64. Lichtman SN, Wang J, Sartor RB, Zhang C, Bender D, Dalldorf FG, Schwab JH. Reactivation of arthritis induced by small bowel bacterial overgrowth in rats: role of cytokines, bacteria, and bacterial polymers. Infect Immun 1995; 63:2295-301.
65. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995;109:1344-67.
66. Choo SY, Antonelli P, Nisperos B, Nepom GT, Hansen JA. Six variants of HLA-B27 identified by isoelectric focusing. Immunogenetics 1986;23:24-9.
67. Breur-Vriesendorp BS, Dekker-Saeys AJ, Ivanyi P. Distribution of HLA-B27 subtypes in patients with ankylosing spondylitis: the disease is associated with a common determinant of the various B27 molecules. Ann Rheum Dis 1987;46:353-6.
68. Lopez de Castro JA. HLA-B27 and HLA-A2 subtypes: structure, evolution and function. Immunol Today 1989;10:239-46.
69. Lopez de Castro JA. Structure, function, and disease association of HLA-B27. Curr Opin Rheumatol 1994;6:371-7.
70. Derhaag PJFM. Genetical factors - other than HLA-B27 - in "HLA-B27-associated diseases." Scand J Rheumatol 1990;(suppl 87):122-6.
71. Robinson WP, van der Linden SM, Khan MA, Rentsch HU, Cats A, Russell A, Thomson G. HLA-Bw60 increases susceptibility to ankylosing spondylitis in HLA-B27+ patients. Arthritis Rheum 1989;32:1135-41.
72. Deshayes P, Geffroy Y, Houdent C, Hetcketsweiler P, Colin R, Cavelier B, Monconduit M, Ropartz C. Manifestations rhumatismales dans 80 cas de maladie de Crohn. Rev Rhum Mal Osteoartic 1976;43:345-55.
73. Crusius JBA, Bing X, Mulder CJJ, Mearin ML, Peña AS. Relevance of haplotypes in the TNF region in celiac disease. Eur Cytok Network 1994;2:168A.
74. Bouma G, Xia B, Crusius JBA, Bioque G, Koutroubakis I, von Blomberg BME, Meuwissen SGM, Pena AS. Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 1996;103:391-6.
75. Bouma G, Crusius JBA, Oudkerk Pool M, Kolkman JJ, von Blomberg BME, Kostense PJ, Giphart MJ, Schreuder GMT, Meuwissen SGM, Pena AS. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles - relevance for inflammatory bowel disease. Scand J Immunol 1996;43: 456-63.
76. Jarvinen P. Occurrence of ankylosing spondylitis in a nationwide series of twins. Arthritis Rheum 1995;38:381-3.
77. Verjans GMGM, van der Linden SM, van Eys GJ, de Waal LP, Kijlstra A. Restriction fragment length polymorphism of the tumor necrosis factor region in patients with ankylosing spondylitis. Arthritis Rheum 1991;34:486-9.
78. Verjans GMGM, Brinkman BM, van Doornik CE, Kijlstra A, Verweij CL. Polymorphism of tumour necrosis factor-alpha (TNF-alpha) at position -308 in relation to ankylosing spondylitis. Clin Exp Immunol 1994;97:45-7.
79. Brinkman BMN. Tumor necrosis factor-alpha: gene polymorphisms and disease [Thesis]. Leiden: Academic University Leiden, 1996:32-6.
80. Mansfield JC, Holden H, Tarlow JK, di Giovine FS, McDowell TL, Wilson AG, Holdsworth CD, Duff GW. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994;106:637-42.
81. Bioque G, Bouma G, Crusius JBA, Koutroubakis I, Kostense PJ, Meuwissen SGM, Pena AS. Evidence for genetic heterogeneity in IBD. 1. The interleukin-1 receptor antagonist in the predisposition to suffer from ulcerative colitis. Eur J Gastroenterol Hepatol 1996;8:105-10.
82. Danis VA, Millington M, Hyland V, Lawford R, Huang Q, Grennan D. Increased frequency of the uncommon allele of a tumour necrosis factor alpha gene polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Dis Markers 1995;12:127-33.
83. Feltkamp TEW. Factors involved in the pathogenesis of HLA-B27 associated arthritis. Scand J Rheum 1995;24:213-7.
84. Inman RD, Johnston ME, Hodge M, Falk J, Helewa A. Postdysenteric reactive arthritis: a clinical and immunogenetic study following an outbreak of salmonellosis. Arthritis Rheum 1988;31:1377-83.
85. Leirisalo-Repo M, Suoranta H. Ten-year follow-up study of patients with Yersinia arthritis. Arthritis Rheum 1988; 31:533-7.
86. Bremell T, Bjelle A, Svedhem A. Rheumatic symptoms following an outbreak of campylobacter enteritis: a five year follow up. Ann Rheum Dis 1991;50:934-8.
87. Lindholm H, Visakorpi R. Late complications after a Yersinia enterocolitica epidemic: a follow up study. Ann Rheum Dis 1991;50:694-6.
88. Thomson GT, de Rubeis DA, Hodge MA, Rajanayagam C, Inman RD. Post-Salmonella reactive arthritis: late clinical sequelae in a point source cohort. Am J Med 1995;98:13-21.
89. Marsal L, Winblad S, Wollheim FA. Yersinia enterocolitica arthritis in southern Sweden: a four-year follow-up study. Br Med J 1981;283:101-3.
90. Toivanen P. Comparisons between various infections triggering reactive arthritis: implications for the pathogenesis. Ann Rheum Dis 1996;55:572A.
91. Leirisalo M, Skylv G, Kousa M, Voipio-Pulkki LM, Suoranta H, Nissila M, Hvidman L, Nielsen ED, Svejgaard A, Tilikainen A, Laitinen O. Followup study on patients with Reiter's disease and reactive arthritis, with special reference to HLA-B27. Arthritis Rheum 1982;25:249-59.
92. Thomson GT, Chiu B, de Rubeis D, Falk J, Inman RD. Immunoepidemiology of post-Salmonella reactive arthritis in a cohort of women. Clin Immunol Immunopathol 1992; 64:227-32.
93. Mattila L, Leirisalo-Repo M, Koskimies S, Granfors K, Siitonen A. Reactive arthritis following an outbreak of Salmonella infection in Finland. Br J Rheumatol 1994;33:1136-41.
94. Herrlinger JD, Asmussen JU. Long term prognosis in yersinia arthritis: clinical and serological findings. Ann Rheum Dis 1992;51:1332-4.
95. Sieper J, Braun J, Wu P, Hauer R, Laitko S. The possible role of Shigella in sporadic enteric reactive arthritis. Br J Rheumatol 1993;32:582-5.
96. Leirisalo-Repo M, Mattila L, Siitonen A, Koskimies S, Granfors K. How strong is the association of reactive arthritis with HLA-B27? Ann Rheum Dis 1996;55:574A.
97. Sieper J, Kingsley GH, Markerhermann E. Aetiological agents and immune mechanisms in enterogenic reactive arthritis. Baillieres Clin Rheumatol 1996;10:105-21.
98. Granfors K, Jalkanen S, von Essen R, Lahesmaa-Rantala R, Isomaki O, Pekkola-Heino K, Merilahti-Palo R, Saario R, Isomaki H, Toivanen A. Yersinia antigens in synovial-fluid cells from patients with reactive arthritis. N Engl J Med 1989;320:216-21.
99. Maki-Ikola O, Yli-Kerttula U, Saario R, Toivanen P, Granfors K. Salmonella specific antibodies in serum and synovial fluid in patients with reactive arthritis. Br J Rheumatol 1992;31:25-9.
100. Mäki-Ikola O, Granfors K. Salmonella-triggered reactive arthritis. Lancet 1992;339:1096-8.
101. Taylor-Robinson D, Gilroy CB, Thomas BJ, Keat AC. Detection of Chlamydia trachomatis DNA in joints of reactive arthritis patients by polymerase chain reaction. Lancet 1992;340:81-2.
102. Rahman MU, Cheema MA, Schumacher HR, Hudson AP. Molecular evidence for the presence of chlamydia in the synovium of patients with Reiter's syndrome. Arthritis Rheum 1992;35:521-9.
103. Wilkinson NZ, Kingsley G, Ward ME. Detection of Chlamydia pneumoniae and Chlamydia trachomatis in the joints of patients with arthritis. Ann Rheum Dis 1996;55:571A-2A.
104. Sieper J, Braun J. Pathogenesis of spondylarthropathies: persistent bacterial antigen, autoimmunity, or both? Arthritis Rheum 1995;38:1547-54.
105. Mertz A, Daser A, Skurnik M, Wiesmüller K-H, Braun J, Appel H, Bratford S, Wu P, Distler A, Sieper J. The evolutionary conserved ribosomal protein L23 and the cationic urease β-subunit of Yersinia enterocolitica 0:3 belong to the immunodominant antigens in Yersinia-triggered reactive arthritis: implications for autoimmunity. Mol Med 1994;1:44-55.
106. Pfeifer JD, Wick MJ, Roberts RL, Findlay K, Normark SJ, Harding CV. Phagocytic processing of bacterial antigens for class IMHC presentation to T cells. Nature 1993;361:359-62.
107. Pope M, Kotlarski I, Doherty K. Induction of Lyt-2+ cytotoxic T lymphocytes following primary and secondary Salmonella infection. Immunology 1994;81:177-82.
108. Hermann E, Yu DT, Meyerzum Büschenfelde K-H, Fleischer B. HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet 1993;342:646-50.
109. Hermann E, Ackermann B, Duchmann R, Meyer zum Büschenfelde K-H. Synovial fluid MHC-unrestricted gamma delta-T lymphocytes contribute to antibacterial and anti-self cytotoxicity in the spondylarthropathies. Clin Exp Rheumatol 1995;13:187-91.
110. Geczy AF, McGuigan LE, Sullivan JS, Edmonds JP. Cytotoxic T lymphocytes against disease-associated determinant(s) in ankylosing spondylitis. J Exp Med 1986;164:932-7.
111. Geczy AF, Edwards CM, McGuigan LE, Sullivan JE. Cross-reacting determinants in ankylosing spondylitis. ISI Atlas Immunol 1988;1:7-10.
112. Benjamin R, Parham P. HLA-B27 and disease: a consequence of inadvertent antigen presentation? Rheum Dis Clin North Am 1992;18:11-21.
113. Geczy AF, Sullivan JS. Possible role of HLA-B27 associated cytotoxic T lymphocyte activity in the pathogenesis of the seronegative arthropathies. Ann Rheum Dis 1995;54:329-30.
114. Pazmany L, Rowland-Jones S, Huet S, Hill A, Sutton J, Murray R, Brooks J, McMichael A. Genetic modulation of antigen presentation by HLA-B27 molecules. J Exp Med 1992;175:361-9.
115. Tussey LG, Rowland-Jones S, Zheng TS, Androlewicz MJ, Cresswell P, Frelinger JA, McMichael AJ. Different MHC class I alleles compete for presentation of overlapping viral epitopes. Immunity 1995;3:65-77.
116. Simon AK, Seipelt E, Sieper J. Divergent T-cell cytokine patterns in inflammatory arthritis. Proc Natl Acad Sci USA 1994;91:8562-6.
117. Kingsley G, Sieper J. Third International Workshop on reactive arthritis 23-26 September 1995, Berlin, Germany - an overview. Ann Rheum Dis 1996;55:564-70.
118. Seager K, Bashir HV, Geczy AF, Edmonds J, de Vere-Tyndall A. Evidence for a specific B27-associated cell surface marker on lymphocytes of patients with ankylosing spondylitis. Nature 1979;277:68-70.
119. Geczy AF, Alexander K, Bashir HV, Edmonds J. A factor(s) in Klebsiella culture filtrates specifically modifies an HLA-B27 associated cell-surface component. Nature 1980; 283:782-4.
120. Trull AK, Ebringer R, Panayi GS, Colthorpe D, James DC, Ebringer A. IgA antibodies to Klebsiella pneumoniae in ankylosing spondylitis. Scand J Rheumatol 1983;12:249-53.
121. Sahly H, Podschun R, Sass R, Bröker B, Kekow J, Gross WL, Ullmann U. Serum antibodies to Klebsiella capsular polysaccharides in ankylosing spondylitis. Arthritis Rheum 1994;37:754-9.
122. Schwimmbeck PL, Yu DTY, Oldstone MBA. Autoantibodies to HLA B27 in the sera of HLA B27 patients with ankylosing spondylitis and Reiter's syndrome: molecular mimicry with Klebsiella pneumoniae as potential mechanism of autoimmune disease. J Exp Med 1987;166:173-81.
123. Fielder M, Pirt SJ, Tarpey I, Wilson C, Cunningham P, Ettelaie C, Binder A, Bansal S, Ebringer A. Molecular mimicry and ankylosing spondylitis: possible role of a novel sequence in pullulanase of Klebsiella pneumoniae. FEBS Lett 1995;369:243-8.
124. Nissila M, Lahesmaa R, Leirisalo-Repo M, Lehtinen K, Toivanen P, Granfors K. Antibodies to Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis in ankylosing spondylitis: effect of sulfasalazine treatment. J Rheumatol 1994;21:2082-7.
125. Mäki-Ikola O, Nissila M, Lehtinen K, Leirisalo-Repo M, Granfors K. IgA1 and IgA2 subclass antibodies against Klebsiella pneumoniae in the sera of patients with peripheral and axial types of ankylosing spondylitis. Ann Rheum Dis 1995;54:631-5.
126. Tsuchiya N, Husby G, Williams RC Jr. Studies of humoral and cell-mediated immunity to peptides shared by HLA-27.1 and Klebsiella pneumoniae nitrogenase in ankylosing spondylitis. Clin Exp Immunol 1989;76:354-60.
127. de Vries DD, Dekker-Saeys AJ, Gyodi E, Bohm U, Ivanyi P. Absence of autoantibodies to peptides shared by HLA-B27.5 and Klebsiella pneumoniae nitrogenase in serum samples from HLA-B27 positive patients with ankylosing spondylitis and Reiter's syndrome. Ann Rheum Dis 1992;51:783-9.
128. Sprenkels SHD, van Kregten E, Feltkamp TEW. IgA antibodies against Klebsiella and other gram-negative bacteria in ankylosing spondylitis and acute anterior uveitis. Clin Rheumatol 1996;15:48-51.
129. Singh B, Dillion T, Lauzon J, Fraga E, Russell AS. Tolerance to the HLA-B27 and Klebsiella pneumoniae crossreactive epitope in mice transgenic for HLA-B2705 and human beta 2-microglobulin. J Rheumatol 1994;21:670-4.
130. Cooper R, Fraser SM, Sturrock RD, Gemmell CG. Raised titres of anti-klebsiella IgA in ankylosing spondylitis, rheumatoid arthritis, and inflammatory bowel disease. Br Med J Clin Res 1988;296:1432-4.
131. Lahesmaa R, Skurnik M, Vaara M, Leirisalo-Repo M, Nissila M, Granfors K, Toivanen P. Molecular mimicry between HLA B27 and Yersinia, Salmonella, Shigella and Klebsiella within the same region of HLA alpha 1-helix. Clin Exp Immunol 1991;86:399-404.
132. Cuvelier CA, Quatacker J, Mielants H, de Vos M, Veys E, Roels HJ. M-cells are damaged and increased in number in inflamed human ileal mucosa. Histopathology 1994;24: 417-26.
133. Pullar T, Hunter JA, Capell HA. Which component of sulphasalazine is active in rheumatoid arthritis? Br Med J 1985; 290:1535-8.
134. Taggart A, Gardiner P, McEvoy F, Hopkins R, Bird H. Which is the active moiety of sulfasalazine in ankylosing spondylitis - a randomized, controlled study. Arthritis Rheum 1996;39:1400-5.
135. Mielants H, Veys EM, Cuvelier C, de Vos M, Botelberghe L. HLA-B27 related arthritis and bowel inflammation. Part 2. Ileocolonoscopy and bowel histology in patients with HLA-B27 related arthritis. J Rheumatol 1985;12:294-8.
136. Mielants H, Veys EM, Joos R, Cuvelier C, de Vos M. Repeat ileocolonoscopy in reactive arthritis. J Rheumatol 1987;14:456-8.
137. Cuvelier C, Barbatis C, Mielants H, de Vos M, Roels H, Veys E. Histopathology of intestinal inflammation related to reactive arthritis. Gut 1987;28:394-401.
138. Mielants H, Veys EM, Cuvelier C, de Vos M. Course of gut inflammation in spondylarthropathies and therapeutic consequences. Baillieres Clin Rheumatol 1996;10:147-64.
139. de Vos M, Mielants H, Cuvelier C, Elewaut A, Veys E. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 1996;110:1696-703.
140. Mielants H, Veys EM, Cuvelier C, de Vos M, Goemaere S, Declercq L, Schatteman L, Elewaut D. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol 1995;22:2273-8.
141. Grillet B, de Clerck L, de Queker J, Rutgeerts P, Geboes K. Systematic ileocolonoscopy and bowel biopsy study in spondylarthropathy. Br J Rheumatol 1987;26:338-40.
142. Simenon G, van Gossum A, Adler M, Rickaert F, Appelboom T. Macroscopic and microscopic gut lesions in seronegative spondyloarthropathies. J Rheumatol 1990;17:1491-4.
143. Leirisalo-Repo M, Turunen U, Stenman S, Helenius P, Seppälä K. High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis Rheum 1994;37:23-31.
144. Leirisalo-Repo M, Turunen U. Evolution of inflammatory bowel disease in spondyloarthropathy. Arthritis Rheum 1995;38:S204.
145. Alonso JC, López-Longo FJ, Lampreave JL, Gonzalez CM, Gonzalez M, Almoguera I, Carreño L. Different abdominal scintigraphy pattern in patients with ulcerative colitis, Crohn's disease and seronegative spondylarthropathies. Br J Rheumatol 1995;34:946-50.
146. Cuvelier C, Mielants H, de Vos M, Veys E, Roels H. Immunoglobulin containing cells in terminal ileum and colorectum of patients with arthritis related gut inflammation. Gut 1988;29:916-25.
147. Cuvelier C, Mielants H, de Vos M, Veys E, Roels H. Major histocompatibility complex class II antigen (HLA-DR) expression by ileal epithelial cells in patients with seronegative spondylarthropathy. Gut 1990;31:545-9.
148. Amor B, Dougados M, Khan MA. Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum Dis Clin North Am 1995;21:117-28.
149. Cuellar ML, Espinoza LR. Management of spondyloarthropathies. Curr Opin Rheumatol 1996;8:288-95.
150. Smith MD, Gibson RA, Brooks PM. Abnormal bowel permeability in ankylosing spondylitis and rheumatoid arthritis. J Rheumatol 1985;12:299-305.
151. Martínez-González O, Cantero-Hinojosa J, Paule-Sastre P, Gómez-Magán JC, Salvatierra-Ríos D. Intestinal permeability in patients with ankylosing spondylitis and their healthy relatives. Br J Rheumatol 1994;33:644-7.
152. Bjarnason I, Peters TJ. Influence of anti-rheumatic drugs on gut permeability and on the gut associated lymphoid tissue. Baillieres Clin Rheumatol 1996;10:165-76.
153. Kaufmann HJ, Taubin HL. NSAID activate quiescent inflammatory bowel disease. Ann Intern Med 1987;107:513-6.
154. Rampton DS, Sladen GE. Relapse of ulcerative proctocolitis during treatment with NSAID. Postgrad Med J 1981;57:297-9.
155. Rampton DS, McNeil NI, Sarner M. Analgesic ingestion and other factors preceding relapse in ulcerative colitis. Gut 1983;24:187-9.
156. Maugars Y, Mathis C, Vilon P, Prost A. Corticosteroid injection of the sacroiliac joint in patients with seronegative spondylarthropathy. Arthritis Rheum 1992;35:564-8.
157. Feltelius N, Hallgren R. Sulphasalazine in ankylosing spondylitis. Ann Rheum Dis 1986;45:396-9.
158. Ferraz MB, Tugwell P, Goldsmith CH, Atra E. Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 1990;17:1482-6.
159. Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, Zeidler H, Kvien TK, Olivieri I, Dijkmans B, Bertouch J, Brooks P, Edmonds J, Major G, Amor B, Calin A. Sulfasalazine in the treatment of spondylarthropathy: a randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618-27.
160. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
161. Barrera P, Boerbooms AMT, Van de Putte LBA, Van der Meer JWM. Effects of antirheumatic agents on cytokines. Semin Arthritis Rheum 1996;25:234-53.
162. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, Eggens U, Distler A, Sieper J. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499-505.
163. Ford DK, Vallis DG. The clinical course of arthritis, associated with ulcerative colitis and regional enteritis. Arthritis Rheum 1959;59:526-36.
164. Fernandez-Herlihy L. The articular manifestations of chronic ulcerative colitis: an analysis of 555 cases. N Engl J Med 1959;261:259-63.
165. McBride JA, King MJ, Baikie AG, Crean GP, Sircus W. Ankylosing spondylitis and chronic inflammatory diseases of the intestines. Br Med J 1963;2:483-6.
166. Ansell BM, Wrighley RAD. Arthritis manifestations in regional enteritis. Ann Rheum Dis 1964;23:64-72.
167. Wright R, Lumsden K, Luntz MH, Sevel D, Truelove SC. Abnormalities of the sacro-iliac joints and uveitis in ulcerative colitis. Q J Med 1965;29:229-36.
168. Nagant de Deux-Chaisnes C, Huaux JP, Fiasse P, de Bruyère M. Ankylosing spondylitis, sacroiliitis, regional enteritis and HL-A27. Lancet 1974;1:1238-9.